Barry D Nelkin

Professor Emeritus

1980 …2019
If you made any changes in Pure, your changes will be visible here soon.

Fingerprint Dive into the research topics where Barry D Nelkin is active. These topic labels come from the works of this person. Together they form a unique fingerprint.

  • 3 Similar Profiles
Calcitonin Medicine & Life Sciences
Small Cell Lung Carcinoma Medicine & Life Sciences
Neoplasms Medicine & Life Sciences
Genes Medicine & Life Sciences
Growth Medicine & Life Sciences
DNA Medicine & Life Sciences
Cells Chemical Compounds
Cell Line Medicine & Life Sciences

Network Recent external collaboration on country level. Dive into details by clicking on the dots.

Research Output 1980 2019

A phase i trial of the VEGF receptor tyrosine kinase inhibitor pazopanib in combination with the MEK inhibitor trametinib in advanced solid tumors and differentiated thyroid cancers

Kurzrock, R., Ball, D. W., Zahurak, M. L., Nelkin, B. D., Subbiah, V., Ahmed, S., O'Connor, A., Karunsena, E., Parkinson, R., Bishop, J. A., Ha, Y., Sharma, R., Gocke, C., Zinner, R., Rudek-Renaut, M., Sherman, S. I. & Azad, N., Sep 15 2019, In : Clinical Cancer Research. 25, 18, p. 5475-5484 10 p.

Research output: Contribution to journalArticle

Vascular Endothelial Growth Factor Receptor
Mitogen-Activated Protein Kinase Kinases
Thyroid Neoplasms
Protein-Tyrosine Kinases
Neoplasms

O-GlcNAcylation is required for mutant KRAS-induced lung tumorigenesis

Taparra, K., Wang, H., Malek, R., Lafargue, A., Barbhuiya, M. A., Wang, X., Simons, B. W., Ballew, M., Nugent, K., Groves, J., Williams, R. D., Shiraishi, T., Verdone, J., Yildirir, G., Henry, R., Zhang, B., Wong, J., Wang, K-H., Nelkin, B. D., Pienta, K. & 3 others, Felsher, D., Zachara, N. E. & Tran, P. T., Nov 1 2018, In : The Journal of clinical investigation. 128, 11, p. 4924-4937 14 p.

Research output: Contribution to journalArticle

Hexosamines
Biosynthetic Pathways
Carcinogenesis
Lung
Glycosylation

Overall survival analysis of EXAM, a phase III trial of cabozantinib in patients with radiographically progressive medullary thyroid carcinoma

Schlumberger, M., Elisei, R., Müller, S., Schöffski, P., Brose, M., Shah, M., Licitra, L., Krajewska, J., Kreissl, M. C., Niederle, B., Cohen, E. E. W., Wirth, L., Ali, H., Clary, D. O., Yaron, Y., Mangeshkar, M., Ball, D. W., Nelkin, B. D. & Sherman, S., Jan 1 2017, In : Annals of Oncology. 28, 11, p. 2813-2819 7 p.

Research output: Contribution to journalArticle

Survival Analysis
Placebos
Survival
Confidence Intervals
Disease-Free Survival

Recent advances in the biology and therapy of medullary thyroid carcinoma

Nelkin, B. D., Jan 1 2017, In : F1000Research. 6, 2184.

Research output: Contribution to journalReview article

Phosphotransferases
Genes
Substrates
Therapeutics
Proteins

Long-Term ERK Inhibition in KRAS-Mutant Pancreatic Cancer Is Associated with MYC Degradation and Senescence-like Growth Suppression

Hayes, T. K., Neel, N. F., Hu, C., Gautam, P., Chenard, M., Long, B., Aziz, M., Kassner, M., Bryant, K. L., Pierobon, M., Marayati, R., Kher, S., George, S. D., Xu, M., Wang-Gillam, A., Samatar, A. A., Maitra, A., Wennerberg, K., Petricoin, E. F., Yin, H. H. & 4 others, Nelkin, B. D., Cox, A. D., Yeh, J. J. & Der, C. J., Jan 11 2016, In : Cancer Cell. 29, 1, p. 75-89 15 p.

Research output: Contribution to journalArticle

Phosphatidylinositol 3-Kinase
Pancreatic Neoplasms
Cell Line
Mitogen-Activated Protein Kinase Kinases
Genetic Testing